Evidence map›Paper›PMID 42383255›Full record

ArticleMolecular therapy. Oncology2026

Natural killer cell-derived extracellular vesicles reprogram cellular human immunity to enhance tumor cytotoxicity.

Frederic St-Denis-Bissonnette, Karan Mediratta, Nicholas Ho, Melanie Kirkby, Andrew Stalker, Gauri Muradia, Amit Shrestha, Michele Ardolino, Seung-Hwan Lee, Dylan Burger and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Frederic St-Denis-BissonnetteBiologic and Radiopharmaceutical Drugs Directorate, Health Canada, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Karan MedirattaDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Nicholas HoDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Melanie KirkbyBiologic and Radiopharmaceutical Drugs Directorate, Health Canada, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Andrew StalkerBiologic and Radiopharmaceutical Drugs Directorate, Health Canada, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Gauri MuradiaBiologic and Radiopharmaceutical Drugs Directorate, Health Canada, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Amit ShresthaDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Michele ArdolinoDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Seung-Hwan LeeDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Dylan BurgerKidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Arvind MerDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Lisheng WangDepartment of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1N 6N5, Canada.
Jessie R LavoieBiologic and Radiopharmaceutical Drugs Directorate, Health Canada, University of Ottawa, Ottawa, ON K1N 6N5, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells are part of the body's first line of defense that rapidly destroy stressed, infected, or cancerous cells. These immune cells release nanosized biological packages called extracellular vesicles (EVs), which transfer molecular signals between cells and influence immune function. Although NK cell-derived EVs (NK92-EVs) have shown the ability to directly kill cancer cells, how they shape the broader human immune response has remained unclear. Here, NK92-EVs were shown to reprogram cellular human immunity to enhance tumor cytotoxicity using single-cell transcriptomics and functional cytotoxicity assays. When human peripheral blood mononuclear cells (PBMCs) from healthy and cancer patients (who exhibit systemic dysregulation) were exposed to NK92-EVs, widespread shifts in gene activity occurred across key immune populations, notably CD8

Indexed as

cellular reprogrammingEVsextracellular vesicles or exosomesimmunomodulationimmunotherapynatural killer cellsNK cellsPBMCsperipheral mononuclear blood cellsscRNA-seqsingle-cell RNA sequencingTNBCtriple-negative breast cancer

Identifiers

PMID42383255
PMCPMC13316585

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.